

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number
WO 2005/080593 A3

(51) International Patent Classification⁷: **C12Q 1/68,**
G01N 33/574

THOMAS, George [US/US]; 422, Hillcrest Drive,
Wyoming, OH 45215 (US).

(21) International Application Number:
PCT/EP2005/001849

(74) Agents: **MOLAC, Béatrice** et al.; Novartis AG, Corporate
Intellectual Property, 4002 Basel (CH).

(22) International Filing Date: 22 February 2005 (22.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/546,856 23 February 2004 (23.02.2004) US

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.

(71) Applicant (*for all designated States except AT, US*): **NO-
VARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel
(CH).

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH**
[AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(71) Applicant (*for all designated States except US*): **NO-
VARTIS FORSCHUNGSSTIFTUNG** [CH/CH];
Zweigniederlassung Friedrich Miescher Institute For
Biomedical Research, Maulbeerstrasse 66, CH-4058 Basel
(CH).

Published:
— *with international search report*


(72) Inventors; and
(75) Inventors/Applicants (*for US only*): **BEUVINK, Iwan**
[NL/CH]; Jakobsweg 22, CH-4105 Biel-Benken (CH).
BOULAY, Anne [FR/FR]; 9 Rue des Prés, F-68730
Blotzheim (FR). **LANE, Heidi** [CH/CH]; Jakobsweg
22, CH-4105 Biel-Benken (CH). **O'REILLY, Terence**
[CA/CH]; Drahtzugstrasse 51, CH-4057 Basel (CH).

(88) Date of publication of the international search report:
24 November 2005

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: P53 WILD-TYPE AS BIOMARKER FOR THE TREATMENT WITH MTOR INHIBITORS IN COMBINATION WITH
A CYTOTOXIC AGENT

(57) Abstract: Provided are biomarkers for determining the sensitivity of proliferative diseases such as cancer to therapeutic agents,
in particular mTOR inhibitors in combination with a cytotoxic agent, in particular a cytotoxic agent which damages or affects the
integrity of DNA.



WO 2005/080593 A3